Related references
Note: Only part of the references are listed.Diversification of the Structural Determinants of Fibroblast Growth Factor-Heparin Interactions IMPLICATIONS FOR BINDING SPECIFICITY
Ruoyan Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Pharmacokinetic Properties of 2nd-Generation Fibroblast Growth Factor-1 Mutants for Therapeutic Application
Xue Xia et al.
PLOS ONE (2012)
Mucositis: The impact, biology and therapeutic opportunities of oral mucositis
Stephen T. Sonis
ORAL ONCOLOGY (2009)
Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies
Parnian Zia-Amirhosseini et al.
PHARMACOTHERAPY (2007)
Intestinal mucositis: mechanisms and management
Dorothy M. Keefe
CURRENT OPINION IN ONCOLOGY (2007)
Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis
N. Blijlevens et al.
ANNALS OF ONCOLOGY (2007)
Palifermin: Role in the prevention of chemotherapy- and radiation-induced mucositis
Anne M. McDonnell et al.
ANNALS OF PHARMACOTHERAPY (2007)
Effect of renal function on the pharmacokinetics of palifermin
B. Gillespie et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers
Parnian Zia-Amirhosseini et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Palifermin for oral mucositis after intensive therapy for hematologic cancers
R Spielberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The effects of keratinocyte growth factor in preclinical models of mucositis
CL Farrell et al.
CELL PROLIFERATION (2002)
Lipoprotein lipase during continuous heparin infusion:: Tissue stores become partially depleted
B Näsström et al.
JOURNAL OF LABORATORY AND CLINICAL MEDICINE (2001)
Pharmacokinetics and pharmacodynamics of recombinant FGF-2 in a phase I trial in coronary artery disease
MA Bush et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Elevation of hepatic transaminases after enoxaparin use: Case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity
MK Carlson et al.
PHARMACOTHERAPY (2001)
Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin
L Pellegrini et al.
NATURE (2000)
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization
J Schlessinger et al.
MOLECULAR CELL (2000)
Share Paper
